# Plain RAG on Cornelia de Lange syndrome 7 (MAU2, OMIM:621570)
model: gemini-3.8-flash   generated: 2026-09-28 20:54

Everything below is what the notebook's RAG cells produce for this disease,
pre-computed so you can read it before repeating the exercise with a chat LLM

## 1. The search
query: `MAU2 gene Cornelia de Lange syndrome 7`

[1] **Clinical study and genetic analysis of Cornelia de Lange ...**  
    https://pmc.ncbi.nlm.nih.gov/articles/PMC10767608/  
    by Y Peng · 2023 · Cited by 6 — Seven genes reportedly cause CdLS. Recent research has reported that loss‐of‐function variants affecting MAU2, which encodes a regulator of the ...

[2] **Pathogenic variants in the cohesin loader subunit MAU2 ...**  
    https://www.nature.com/articles/s41467-026-71177-6  
    by I Parenti · 2026 · Cited by 3 — While NIPBL variants are a major cause of Cornelia de Lange Syndrome (CdLS), the role of MAU2 in disease is unclear. We describe 18 individuals ...

[3] **621570 - CORNELIA DE LANGE SYNDROME 7; CDLS7**  
    https://omim.org/entry/621570  
    Clinical study and genetic analysis of Cornelia de Lange syndrome caused by a novel MAU2 gene variant in a Chinese boy. Molec. Genet. Genomic Med. 12: e2318 ...

[4] **Pathogenic variants in the cohesin loader subunit MAU2 ...**  
    https://scholarlyexchange.childrensmercy.org/cgi/viewcontent.cgi?article=8223&context=papers  
    Our study establishes MAU2 as a CdLS-associated gene and delineates a MAU2-related chromatinopathy with variable expressivity. Cornelia de Lange ...

[5] **NIF | Searching in Literature**  
    https://neuinfo.org/literature/pmid:37962004?rpKey=on  
    Seven genes reportedly cause CdLS. Recent research has reported that loss-of-function variants affecting MAU2, which encodes a regulator of the cohesin complex, ...

[6] **Clinical study and genetic analysis of Cornelia de Lange ...**  
    https://onlinelibrary.wiley.com/doi/abs/10.1002/mgg3.2318  
    by Y Peng · 2024 · Cited by 6 — Seven genes reportedly cause CdLS. Recent research has reported that loss-of-function variants affecting MAU2, which encodes a regulator of the ...

## 2. The context handed to the model
```
[1] Clinical study and genetic analysis of Cornelia de Lange ...
https://pmc.ncbi.nlm.nih.gov/articles/PMC10767608/
by Y Peng · 2023 · Cited by 6 — Seven genes reportedly cause CdLS. Recent research has reported that loss‐of‐function variants affecting MAU2, which encodes a regulator of the ...

[2] Pathogenic variants in the cohesin loader subunit MAU2 ...
https://www.nature.com/articles/s41467-026-71177-6
by I Parenti · 2026 · Cited by 3 — While NIPBL variants are a major cause of Cornelia de Lange Syndrome (CdLS), the role of MAU2 in disease is unclear. We describe 18 individuals ...

[3] 621570 - CORNELIA DE LANGE SYNDROME 7; CDLS7
https://omim.org/entry/621570
Clinical study and genetic analysis of Cornelia de Lange syndrome caused by a novel MAU2 gene variant in a Chinese boy. Molec. Genet. Genomic Med. 12: e2318 ...

[4] Pathogenic variants in the cohesin loader subunit MAU2 ...
https://scholarlyexchange.childrensmercy.org/cgi/viewcontent.cgi?article=8223&context=papers
Our study establishes MAU2 as a CdLS-associated gene and delineates a MAU2-related chromatinopathy with variable expressivity. Cornelia de Lange ...

[5] NIF | Searching in Literature
https://neuinfo.org/literature/pmid:37962004?rpKey=on
Seven genes reportedly cause CdLS. Recent research has reported that loss-of-function variants affecting MAU2, which encodes a regulator of the cohesin complex, ...

[6] Clinical study and genetic analysis of Cornelia de Lange ...
https://onlinelibrary.wiley.com/doi/abs/10.1002/mgg3.2318
by Y Peng · 2024 · Cited by 6 — Seven genes reportedly cause CdLS. Recent research has reported that loss-of-function variants affecting MAU2, which encodes a regulator of the ...
```

## 3. The gene, from the sources

The *MAU2* gene encodes a protein that functions as a regulator of the cellular cohesin complex [1, 5, 6]. In addition, *MAU2* serves as a cohesin loader subunit within the cell [2, 4]. Pathogenic and novel variants in the *MAU2* gene cause Cornelia de Lange syndrome, linking it directly to Cornelia de Lange syndrome 7 (CDLS7) [3, 4]. While variants in *NIPBL* are a major cause of Cornelia de Lange syndrome, studies demonstrate that loss-of-function variants affecting *MAU2* also result in the condition [1, 2, 5]. Findings establish *MAU2* as a Cornelia de Lange syndrome-associated gene and delineate a *MAU2*-related chromatinopathy characterized by variable expressivity [4]. Consequently, *MAU2* is recognized among the genes that reportedly cause Cornelia de Lange syndrome [1, 3, 5, 6].

*tokens in 607, out 1962*

## 4. The gene, closed book (no sources; beware hallucinations)

factor).
    *   **Gene Product:** MAU2 protein (formerly SCC4), a TPR-containing regulatory protein.
    *   **Function:** MAU2 binds to NIPBL to form the canonical cohesin loading complex (heterodimer). This complex loads the multimeric cohesin ring (SMC1A, SMC3, RAD21, STAG) onto chromatin. This loading is vital for:
        *   Sister chromatid cohesion during cell division.
        *   Genome organization and chromatin looping (topologically associating domains, TADs).
        *   Transcriptional regulation of developmental genes.
        *   DNA double-strand break repair.
    *   **Disease Mechanism (Variants):**
        *   Heterozygous *de novo

## 5. Which patient? Three independent rounds, same prompt

### Round 1  (picked: P01)

Based on the provided sources, here is the clinical evaluation:

### 1. Rule In / Rule Out for Each Patient

The provided sources confirm that loss-of-function or pathogenic variants in *MAU2* cause Cornelia de Lange syndrome 7 (CDLS7) [1, 2, 3, 4, 5, 6] and note "variable expressivity" across described individuals [2, 4]. However, the sources do **not** report any specific clinical features, signs, symptoms, diagnostic criteria, or Human Phenotype Ontology (HPO) terms for CDLS7 [1, 2, 3, 4, 5, 6]. 

Consequently, using strictly the provided text:
* **P01**: Cannot be ruled in or ruled out; the sources provide no phenotypic data for comparison [1–6].
* **P02**: Cannot be ruled in or ruled out; the sources provide no phenotypic data for comparison [1–6].
* **P03**: Cannot be ruled in or ruled out; the sources provide no phenotypic data for comparison [1–6].
* **P04**: Cannot be ruled in or ruled out; the sources provide no phenotypic data for comparison [1–6].
* **P05**: Cannot be ruled in or ruled out; the sources provide no phenotypic data for comparison [1–6].
* **P06**: Cannot be ruled in or ruled out; the sources provide no phenotypic data for comparison [1–6].
* **P07**: Cannot be ruled in or ruled out; the sources provide no phenotypic data for comparison [1–6].
* **P08**: Cannot be ruled in or ruled out; the sources provide no phenotypic data for comparison [1–6].
* **P09**: Cannot be ruled in or ruled out; the sources provide no phenotypic data for comparison [1–6].
* **P10**: Cannot be ruled in or ruled out; the sources provide no phenotypic data for comparison [1–6].

---

### 2. Single Most Likely Patient and Probability

* **Most Likely Patient**: None can be identified as more likely than any other based solely on the sources provided. 
* **Probability**: Since it is given that exactly one of the 10 patients has CDLS7 and the sources provide no phenotypic or distinguishing details [1–6], every patient has an identical prior probability of **1/10 (10% or 0.10)**. Under the provided texts, any chosen patient would have only a 10% probability of being correct.

---

### 3. Facts Needed to Be Confident (Which the Sources Do Not Provide)

To confidently identify the correct patient, the following missing information would be required:
1. **Clinical and phenotypic descriptions of CDLS7**: The sources note that 18 individuals were evaluated [2] and establish a *MAU2*-related chromatinopathy with variable expressivity [4], but they do not list any of the physical, developmental, or dysmorphic features associated with these individuals [1–6].
2. **Cardinal and characteristic HPO terms**: A detailed breakdown of HPO terms or frequency of clinical findings in *MAU2* variant carriers (such as specific craniofacial, growth, limb, or neurodevelopmental features).
3. **Genotypic data for the patients**: Confirmation of whether any patient carries a causative loss-of-function or pathogenic variant in *MAU2* [1, 2, 3, 4, 5, 6].

--------------------------------------------------------------------------------

### Round 2  (picked: P01)

Based strictly on the provided sources, here is the clinical genetic assessment:

### 1. Patient Evaluation (Ruling In or Out)

The provided sources establish that loss-of-function/pathogenic variants in *MAU2* cause Cornelia de Lange syndrome 7 (CDLS7) and delineate a *MAU2*-related chromatinopathy with variable expressivity [1, 2, 3, 4, 5, 6]. However, the sources **do not provide any phenotypic descriptions, clinical signs, or HPO terms** for CDLS7 [1, 2, 3, 4, 5, 6]. 

* **P01:** Cannot be ruled in or ruled out. The sources do not describe any clinical features to evaluate this patient's presentation [1, 2, 3, 4, 5, 6].
* **P02:** Cannot be ruled in or ruled out. The sources do not describe any clinical features to evaluate this patient's presentation [1, 2, 3, 4, 5, 6].
* **P03:** Cannot be ruled in or ruled out. The sources do not describe any clinical features to evaluate this patient's presentation [1, 2, 3, 4, 5, 6].
* **P04:** Cannot be ruled in or ruled out. The sources do not describe any clinical features to evaluate this patient's presentation [1, 2, 3, 4, 5, 6].
* **P05:** Cannot be ruled in or ruled out. The sources do not describe any clinical features to evaluate this patient's presentation [1, 2, 3, 4, 5, 6].
* **P06:** Cannot be ruled in or ruled out. The sources do not describe any clinical features to evaluate this patient's presentation [1, 2, 3, 4, 5, 6].
* **P07:** Cannot be ruled in or ruled out. The sources do not describe any clinical features to evaluate this patient's presentation [1, 2, 3, 4, 5, 6].
* **P08:** Cannot be ruled in or ruled out. The sources do not describe any clinical features to evaluate this patient's presentation [1, 2, 3, 4, 5, 6].
* **P09:** Cannot be ruled in or ruled out. The sources do not describe any clinical features to evaluate this patient's presentation [1, 2, 3, 4, 5, 6].
* **P10:** Cannot be ruled in or ruled out. The sources do not describe any clinical features to evaluate this patient's presentation [1, 2, 3, 4, 5, 6].

---

### 2. Single Most Likely Patient and Probability

* **Most Likely Patient:** None can be distinguished over the others based solely on the sources. If forced to nominate one arbitrarily (e.g., **P01**), it cannot be favored over any other patient.
* **Probability:** **10% (0.10 or 1 in 10)**. Because exactly one patient among the 10 has the condition and the sources contain zero differentiating clinical or genetic details for any candidate, every patient has an equal prior probability of 10%.

---

### 3. Missing Facts Needed for Confidence

To confidently identify the correct patient, the following information (not contained in the sources) is required:
1. **Specific phenotypic spectrum/HPO terms:** The phenotypic characteristics, dysmorphic facial features, and malformations documented in the 18 individuals described by Parenti et al. [2] and the patient described by Peng et al. [1, 3, 6].
2. **Genetic sequencing results:** Patient-specific sequencing data confirming a pathogenic/loss-of-function variant in *MAU2* [1, 2, 3, 4, 5, 6].
3. **Phenotypic differentiation:** Information specifying how the *MAU2*-related phenotype differs from classic CdLS caused by *NIPBL* or the other five CdLS-associated genes [1, 2, 5, 6].

--------------------------------------------------------------------------------

### Round 3  (picked: P01)

Based on the provided sources, here is the clinical genetic assessment:

### 1. Patient Evaluation (Ruling In/Out)
The provided sources establish that pathogenic loss-of-function variants in *MAU2* cause Cornelia de Lange syndrome 7 (CDLS7) / a MAU2-related chromatinopathy with variable expressivity [1, 2, 3, 4, 5, 6]. However, none of the sources provide any specific clinical features, signs, symptoms, or Human Phenotype Ontology (HPO) terms associated with the syndrome. 

* **P01**: **Cannot be ruled in or ruled out.** The sources do not report clinical features or HPO terms for CDLS7 to compare against this profile [1–6].
* **P02**: **Cannot be ruled in or ruled out.** The sources contain no phenotypic descriptions for CDLS7 [1–6].
* **P03**: **Cannot be ruled in or ruled out.** The sources contain no phenotypic descriptions for CDLS7 [1–6].
* **P04**: **Cannot be ruled in or ruled out.** The sources contain no phenotypic descriptions for CDLS7 [1–6].
* **P05**: **Cannot be ruled in or ruled out.** The sources contain no phenotypic descriptions for CDLS7 [1–6].
* **P06**: **Cannot be ruled in or ruled out.** The sources contain no phenotypic descriptions for CDLS7 [1–6].
* **P07**: **Cannot be ruled in or ruled out.** The sources contain no phenotypic descriptions for CDLS7 [1–6].
* **P08**: **Cannot be ruled in or ruled out.** The sources contain no phenotypic descriptions for CDLS7 [1–6].
* **P09**: **Cannot be ruled in or ruled out.** The sources contain no phenotypic descriptions for CDLS7 [1–6].
* **P10**: **Cannot be ruled in or ruled out.** The sources contain no phenotypic descriptions for CDLS7 [1–6].

---

### 2. Single Most Likely Patient and Probability
* **Most Likely Patient**: None of the 10 patients can be clinically distinguished from the others using solely the provided sources. 
* **Probability**: Since exactly one of the 10 individuals has CDLS7 and the sources provide zero distinguishing clinical data, any individual patient (e.g., P01, P02, etc.) has an identical probability of **10% (1/10 or 0.10)**.

---

### 3. Facts Needed to Reach a Confident Diagnosis
To achieve a confident diagnosis using the provided literature, the following information is missing:
1. **Specific Phenotypic Data for CDLS7**: The actual clinical presentations, cardinal features, and HPO term frequencies of the 18 individuals from the Parenti et al. cohort [2, 4] and the individual described by Peng et al. [1, 3, 6], which are referenced by title only and omitted from the source text.
2. **Patient Molecular Genetic Data**: Sequencing or copy number variant data confirming a pathogenic loss-of-function variant in *MAU2* for the individual in question [1, 4, 5].

--------------------------------------------------------------------------------

picks across rounds: ['P01', 'P01', 'P01']
